search
Back to results

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Azilsartan Medoxomil Low-dose
Losartan
Placebo for Azilsartan Medoxomil
Placebo for Losartan
antihypertension medication - Add-on Therapy
Azilsartan Medoxomil Medium-dose
Azilsartan Medoxomil High-dose
Sponsored by
Arbor Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Pediatric Hypertension, High Blood Pressure, Hypertension, Pediatric, Primary Hypertension, Secondary Hypertension

Eligibility Criteria

6 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The subject has hypertension (primary or secondary) defined as clinic Seated Diastolic BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by age, gender, height) if chronic renal disease, diabetes, heart failure or hypertensive target organ damage is present

    1. If currently treated: The subject has a documented historical diagnosis of hypertension AND a post-washout clinic Seated Diastolic BP meeting the above criteria on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)
    2. If currently untreated: The subject has elevated Seated Diastolic BP meeting the above criteria on 3 separate occasions before Randomization, including on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)
  • The subject is male or female and aged 6 to <18 years at Baseline and weighs at least 25 kg
  • The subject agrees to continue their previously implemented nonpharmacological life style modifications if begun prior to Screening. Note: For subjects participating in a weight loss program, the weight maintenance

Exclusion Criteria:

  • The subject has a clinic Seated Diastolic BP greater than 15 mm Hg and/or Seated Diastolic BP greater than 10 mm Hg above the 99th percentile for age, gender, and height as confirmed by the average (arithmetic mean) of 3 serial clinic seated BP measurements at Screening/Visit 1
  • The subject has a diagnosis of malignant or accelerated hypertension
  • The subject is currently treated with more than 2 antihypertensive agents
  • The subject or parent/legal guardian is not willing for the subject's previous antihypertensive medications to be stopped
  • The subject has participated in the intensive, active weight-loss phase of a weight-loss program within 30 days prior to Screening/Visit 1
  • The subject has any of the following: severe renal impairment (eGFR <30 mL/min/1.73 m2 by the Schwartz formula); is currently undergoing dialysis treatment; renovascular disease affecting both kidneys or a solitary kidney; severe nephrotic syndrome not in remission; or serum albumin <2.5 g/dL
  • The subject has a history or clinical manifestations of severe cardiovascular, hepato-biliary, gastrointestinal, endocrine-metabolic (e.g., hyperthyroidism, Cushing's syndrome), hematologic, immunologic, genito-urinary, or psychiatric disease, cancer, and/or any conditions that would interfere with the health status of the subject through study participation, or would jeopardize study integrity in the opinion of the investigator
  • The subject is suffering from uncorrected coarctation of the aorta, or hemodynamically significant left ventricular outflow tract obstruction due to eg, aortic valvular disease, or is likely to undergo a procedure known to affect blood pressure (eg, repair of arterial anomalies) during the course of the study
  • The subject is poorly controlled diabetic defined as having a glycosylated hemoglobin value >8.5% at Screening/Visit 1
  • The subject has hyperkalemia as defined by the central laboratory's normal reference range or any pertinent electrolyte disorders at Screening/Visit

Sites / Locations

  • Advanced Research Center, INC
  • Direct Helpers Research Center
  • JDH Medical Group LLC
  • University of Miami/Jackson Memorial Hospital
  • Medical Research Center of Miami II, Inc.
  • Pioneer Clinical Research
  • Georgia Clinical Research
  • Zoe Center for Pediatrics
  • University of Louisville
  • David M. Headley, MD PA
  • Mount Sinai PRIME
  • Medical University of South Carolina (MUSC)
  • Memphis and Shelby County Pediatric Group
  • Southeast Texas Clinical Research Center
  • Texas Children's Heart Center
  • Ericksen Research & Development, LLC
  • Mid-Columbia Research
  • Hospital Italiano
  • Hospital de Niños
  • Clinica de Nefrologia, Urologia y Enf. Cardiovasculares S A
  • Clínica Nefrokids Ltda
  • Hospital São Lucas da PUCRS
  • Instituto de Cardiologia do Rio Grande do Sul
  • Fundação José Luiz Egydio Setúbal
  • Hospital Samaritano
  • Eurolatino Pesquisas Médicas Ltda.
  • SHATPPD-Ruse EOOD
  • Fundacion Oftalmologica de Santander - FOSCAL
  • Fundacion Valle del Lili
  • Fundacion Hospitalaria San Vicente de Paul
  • Hospital Pablo Tobón Uribe
  • Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA"
  • Principal SMO Kft.
  • Svabhegy Plusz Gyermekegeszsegugyi Kozpont
  • Szent Lukacs Korhaz Dombovar
  • Prehospital Med Kft.
  • Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Kozp.
  • Ospedale Pediatrico Giovanni XXIII
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
  • A.R.N.A.S. Ospedale Civico e Benfratelli, G. Cristina e M.Ascoli
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
  • Hospital General de Mexico
  • Accelerium S. de R.L. de C.V.
  • Centro de Investigacion Clinica Chapultepec S.A. de C.V.
  • SPZOZ Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa
  • Uniwersytecki Szpital Dziecięcy w Krakowie
  • NZOZ TRI-medica
  • Praktyka Lekarzy Rodzinnych R.Jadach, M.Domanski NZOZ
  • LCS Clinical Research Unit
  • Soweto Clinical Trial Centre
  • Netcare St. Anne's Hospital
  • Groote Schuur Hospital E13 Renal Unit
  • Clinical Projects Research SA (PTY) LTD
  • CRISMO Bertha Gxowa Research Centre
  • Cukurova University Medical Faculty
  • Gazi University Medical Faculty
  • Istanbul University Istanbul Medical Faculty
  • Dokuz Eylul University Medicine Faculty
  • Erciyes University Medical Faculty
  • Celal Bayar University Medical Faculty
  • CMI Chernivtsi City Children Clinical Hospital
  • Regional Children CH Cardiology Department Kharkiv NMU
  • SI National Research Center of Radiation Medicine of NAMSU
  • USPC of ES EO&T Transplantation of MHU
  • HSEI of Ukraine UMSA
  • SSU Division MU Ch of pediatrics
  • Vynnitsa Regional Children CH pediatric department № 1 M.I. Pyrogov NMU
  • CI Zaporizhzhia City Multibranch Children Hospital #5
  • CI Zaporizhzhia Regional Clinical Children Hospital of ZRC

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Experimental

Other

Active Comparator

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Double-blind: Azilsartan Medoxomil - Low dose

Double blind phase: Losartan

WITHDRAWAL Phase: Azilsartan medoxomil LOW-dose

WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil LOW DOSE

Open Label Phase: Azilsartan Medoxomil

Open Label Phase: "Other"

Withdrawal Phase: Losartan 50 mg

Withdrawal Phase: PLACEBO to Losartan

Double-blind: Azilsartan Medoxomil - Medium dose

Double-blind: Azilsartan Medoxomil - High dose

WITHDRAWAL Azilsartan Medoxomil - Medium dose

WITHDRAWAL Azilsartan Medoxomil - High dose

WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil MEDIUM DOSE

WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil HIGH DOSE

Arm Description

6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.

6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.

Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blind OR to be switched to placebo.

PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil LOW dose) in Double blind then randomized (1:1) to placebo for withdrawal phase

Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)

If add-on therapy is needed, a calcium channel blocker, such as amlodipine; a diuretic, such as hydrochlorothiazide; or a beta-blocker such as metoprolol will be determined per the investigator's clinical judgment.

Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.

Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.

6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.

6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M

Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double blind OR to be switched to placebo.

Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double blind OR to be switched to placebo.

PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil MEDIUM dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase

PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil HIGH dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase

Outcomes

Primary Outcome Measures

Change in Blood Pressure
Change from Week 6/Final Visit of the double-blindPhase to Week 8/Final Visit of the WD Phase in trough clinic seated diastolic blood pressure between azilsartan medoxomil and placebo

Secondary Outcome Measures

Change in blood Pressure relative to the comparator
Change from Week 6/Final Visit of the double-blind Phase to Week 8/Final Visit of the withdrawal phase in trough clinic seated systolic blood pressure and mean arterial pressure (MAP) between azilsartan medoxomil and placebo.

Full Information

First Posted
September 8, 2014
Last Updated
February 13, 2023
Sponsor
Arbor Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02235909
Brief Title
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
Official Title
A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
December 19, 2014 (Actual)
Primary Completion Date
November 27, 2019 (Actual)
Study Completion Date
September 27, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Arbor Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which is in the same class of drug and is approved for use in the pediatric population aged 6 years and older. Approximately 260 subjects will participate in a 6-week, double-blind, randomized, treatment phase, followed by a 2-week, double-blind, randomized, placebo-controlled withdrawal phase. A 44-week, open-label extension in which all subjects will receive azilsartan and other antihypertensive medications (if needed). Blood pressure will be assessed throughout the study.
Detailed Description
The purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which the same class of drug and is approved for use in the pediatric population aged 6 years and older. Approximately 260 subjects will participate in a 6-week, double-blind, randomized, treatment phase, followed by a 2-week, double-blind, randomized, placebo-controlled withdrawal phase. This study also includes a 44-week, open-label extension Phase in which all subjects will receive azilsartan and other antihypertensive medications (if needed) in order to reach an optimal blood pressure. Blood pressure will be assessed in the clinic throughout the study, and subjects may also participate in a 24-hour ambulatory blood pressure monitoring procedure at baseline, at the end of the double-blind Phase and at the end of the open-label Phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Pediatric Hypertension, High Blood Pressure, Hypertension, Pediatric, Primary Hypertension, Secondary Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
There are 3 phases in this study. Double-blind, withdrawal phase, and open-label phase.
Masking
ParticipantCare ProviderInvestigator
Masking Description
Double-blind masking in the Double Blind Phase and Withdrawal Phase.
Allocation
Randomized
Enrollment
215 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Double-blind: Azilsartan Medoxomil - Low dose
Arm Type
Experimental
Arm Description
6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.
Arm Title
Double blind phase: Losartan
Arm Type
Active Comparator
Arm Description
6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.
Arm Title
WITHDRAWAL Phase: Azilsartan medoxomil LOW-dose
Arm Type
Active Comparator
Arm Description
Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blind OR to be switched to placebo.
Arm Title
WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil LOW DOSE
Arm Type
Placebo Comparator
Arm Description
PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil LOW dose) in Double blind then randomized (1:1) to placebo for withdrawal phase
Arm Title
Open Label Phase: Azilsartan Medoxomil
Arm Type
Experimental
Arm Description
Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)
Arm Title
Open Label Phase: "Other"
Arm Type
Other
Arm Description
If add-on therapy is needed, a calcium channel blocker, such as amlodipine; a diuretic, such as hydrochlorothiazide; or a beta-blocker such as metoprolol will be determined per the investigator's clinical judgment.
Arm Title
Withdrawal Phase: Losartan 50 mg
Arm Type
Active Comparator
Arm Description
Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
Arm Title
Withdrawal Phase: PLACEBO to Losartan
Arm Type
Placebo Comparator
Arm Description
Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
Arm Title
Double-blind: Azilsartan Medoxomil - Medium dose
Arm Type
Experimental
Arm Description
6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.
Arm Title
Double-blind: Azilsartan Medoxomil - High dose
Arm Type
Experimental
Arm Description
6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M
Arm Title
WITHDRAWAL Azilsartan Medoxomil - Medium dose
Arm Type
Experimental
Arm Description
Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double blind OR to be switched to placebo.
Arm Title
WITHDRAWAL Azilsartan Medoxomil - High dose
Arm Type
Experimental
Arm Description
Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double blind OR to be switched to placebo.
Arm Title
WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil MEDIUM DOSE
Arm Type
Experimental
Arm Description
PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil MEDIUM dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
Arm Title
WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil HIGH DOSE
Arm Type
Experimental
Arm Description
PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil HIGH dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
Intervention Type
Drug
Intervention Name(s)
Azilsartan Medoxomil Low-dose
Other Intervention Name(s)
AZM, AR14, AZM-L
Intervention Type
Drug
Intervention Name(s)
Losartan
Other Intervention Name(s)
Cozaar
Intervention Type
Drug
Intervention Name(s)
Placebo for Azilsartan Medoxomil
Other Intervention Name(s)
sugar pill
Intervention Type
Drug
Intervention Name(s)
Placebo for Losartan
Other Intervention Name(s)
sugar pill
Intervention Type
Drug
Intervention Name(s)
antihypertension medication - Add-on Therapy
Intervention Description
add-on therapy (e.g., a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) per PI's clinical judgment.
Intervention Type
Drug
Intervention Name(s)
Azilsartan Medoxomil Medium-dose
Other Intervention Name(s)
AZM, AR14, AZM-M
Intervention Type
Drug
Intervention Name(s)
Azilsartan Medoxomil High-dose
Other Intervention Name(s)
AZM, AR14, AZM-H
Primary Outcome Measure Information:
Title
Change in Blood Pressure
Description
Change from Week 6/Final Visit of the double-blindPhase to Week 8/Final Visit of the WD Phase in trough clinic seated diastolic blood pressure between azilsartan medoxomil and placebo
Time Frame
Double-Blind and Withdrawal Phase
Secondary Outcome Measure Information:
Title
Change in blood Pressure relative to the comparator
Description
Change from Week 6/Final Visit of the double-blind Phase to Week 8/Final Visit of the withdrawal phase in trough clinic seated systolic blood pressure and mean arterial pressure (MAP) between azilsartan medoxomil and placebo.
Time Frame
Double Blind and Withdrawal Phase

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject has hypertension (primary or secondary) defined as clinic Seated Diastolic BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by age, gender, height) if chronic renal disease, diabetes, heart failure or hypertensive target organ damage is present If currently treated: The subject has a documented historical diagnosis of hypertension AND a post-washout clinic Seated Diastolic BP meeting the above criteria on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring) If currently untreated: The subject has elevated Seated Diastolic BP meeting the above criteria on 3 separate occasions before Randomization, including on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring) The subject is male or female and aged 6 to <18 years at Baseline and weighs at least 25 kg The subject agrees to continue their previously implemented nonpharmacological life style modifications if begun prior to Screening. Note: For subjects participating in a weight loss program, the weight maintenance Exclusion Criteria: The subject has a clinic Seated Diastolic BP greater than 15 mm Hg and/or Seated Diastolic BP greater than 10 mm Hg above the 99th percentile for age, gender, and height as confirmed by the average (arithmetic mean) of 3 serial clinic seated BP measurements at Screening/Visit 1 The subject has a diagnosis of malignant or accelerated hypertension The subject is currently treated with more than 2 antihypertensive agents The subject or parent/legal guardian is not willing for the subject's previous antihypertensive medications to be stopped The subject has participated in the intensive, active weight-loss phase of a weight-loss program within 30 days prior to Screening/Visit 1 The subject has any of the following: severe renal impairment (eGFR <30 mL/min/1.73 m2 by the Schwartz formula); is currently undergoing dialysis treatment; renovascular disease affecting both kidneys or a solitary kidney; severe nephrotic syndrome not in remission; or serum albumin <2.5 g/dL The subject has a history or clinical manifestations of severe cardiovascular, hepato-biliary, gastrointestinal, endocrine-metabolic (e.g., hyperthyroidism, Cushing's syndrome), hematologic, immunologic, genito-urinary, or psychiatric disease, cancer, and/or any conditions that would interfere with the health status of the subject through study participation, or would jeopardize study integrity in the opinion of the investigator The subject is suffering from uncorrected coarctation of the aorta, or hemodynamically significant left ventricular outflow tract obstruction due to eg, aortic valvular disease, or is likely to undergo a procedure known to affect blood pressure (eg, repair of arterial anomalies) during the course of the study The subject is poorly controlled diabetic defined as having a glycosylated hemoglobin value >8.5% at Screening/Visit 1 The subject has hyperkalemia as defined by the central laboratory's normal reference range or any pertinent electrolyte disorders at Screening/Visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
steve Caras, MD
Organizational Affiliation
Arbor Pharmaceuticals, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Advanced Research Center, INC
City
Anaheim
State/Province
California
ZIP/Postal Code
92805
Country
United States
Facility Name
Direct Helpers Research Center
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
JDH Medical Group LLC
City
Miami
State/Province
Florida
ZIP/Postal Code
33125
Country
United States
Facility Name
University of Miami/Jackson Memorial Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Medical Research Center of Miami II, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Pioneer Clinical Research
City
North Miami
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Facility Name
Georgia Clinical Research
City
Snellville
State/Province
Georgia
ZIP/Postal Code
30078
Country
United States
Facility Name
Zoe Center for Pediatrics
City
Thomaston
State/Province
Georgia
ZIP/Postal Code
30286
Country
United States
Facility Name
University of Louisville
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
David M. Headley, MD PA
City
Port Gibson
State/Province
Mississippi
ZIP/Postal Code
39150
Country
United States
Facility Name
Mount Sinai PRIME
City
Lake Success
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Medical University of South Carolina (MUSC)
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Memphis and Shelby County Pediatric Group
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38116
Country
United States
Facility Name
Southeast Texas Clinical Research Center
City
Beaumont
State/Province
Texas
ZIP/Postal Code
77701
Country
United States
Facility Name
Texas Children's Heart Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Ericksen Research & Development, LLC
City
Clinton
State/Province
Utah
ZIP/Postal Code
84015
Country
United States
Facility Name
Mid-Columbia Research
City
Richland
State/Province
Washington
ZIP/Postal Code
99352
Country
United States
Facility Name
Hospital Italiano
City
Ciudad Autonoma
State/Province
Buenos Aires
ZIP/Postal Code
1181
Country
Argentina
Facility Name
Hospital de Niños
City
Ciudad Autonoma
State/Province
Buenos Aires
ZIP/Postal Code
C1425EFD
Country
Argentina
Facility Name
Clinica de Nefrologia, Urologia y Enf. Cardiovasculares S A
City
Santa Fe
ZIP/Postal Code
S3000EPV
Country
Argentina
Facility Name
Clínica Nefrokids Ltda
City
Curitiba
ZIP/Postal Code
80240-060
Country
Brazil
Facility Name
Hospital São Lucas da PUCRS
City
Porto Alegre
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Instituto de Cardiologia do Rio Grande do Sul
City
Porto Alegre
ZIP/Postal Code
90620-001
Country
Brazil
Facility Name
Fundação José Luiz Egydio Setúbal
City
São Paulo
ZIP/Postal Code
01227-200
Country
Brazil
Facility Name
Hospital Samaritano
City
São Paulo
ZIP/Postal Code
01232-010
Country
Brazil
Facility Name
Eurolatino Pesquisas Médicas Ltda.
City
Uberlândia
ZIP/Postal Code
38411-186
Country
Brazil
Facility Name
SHATPPD-Ruse EOOD
City
Ruse
ZIP/Postal Code
7002
Country
Bulgaria
Facility Name
Fundacion Oftalmologica de Santander - FOSCAL
City
Bucaramanga
Country
Colombia
Facility Name
Fundacion Valle del Lili
City
Cali
Country
Colombia
Facility Name
Fundacion Hospitalaria San Vicente de Paul
City
Medellin
Country
Colombia
Facility Name
Hospital Pablo Tobón Uribe
City
Medellin
Country
Colombia
Facility Name
Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA"
City
Medellin
Country
Colombia
Facility Name
Principal SMO Kft.
City
Baja
ZIP/Postal Code
6500
Country
Hungary
Facility Name
Svabhegy Plusz Gyermekegeszsegugyi Kozpont
City
Budapest
ZIP/Postal Code
1037
Country
Hungary
Facility Name
Szent Lukacs Korhaz Dombovar
City
Dombovar
ZIP/Postal Code
7200
Country
Hungary
Facility Name
Prehospital Med Kft.
City
Miskolc
ZIP/Postal Code
3526
Country
Hungary
Facility Name
Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Kozp.
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Facility Name
Ospedale Pediatrico Giovanni XXIII
City
Bari
ZIP/Postal Code
70125
Country
Italy
Facility Name
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
City
Milano
ZIP/Postal Code
20122
Country
Italy
Facility Name
A.R.N.A.S. Ospedale Civico e Benfratelli, G. Cristina e M.Ascoli
City
Palermo
Country
Italy
Facility Name
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
City
Durango
ZIP/Postal Code
34000
Country
Mexico
Facility Name
Hospital General de Mexico
City
Mexico City
Country
Mexico
Facility Name
Accelerium S. de R.L. de C.V.
City
Monterrey
ZIP/Postal Code
6400
Country
Mexico
Facility Name
Centro de Investigacion Clinica Chapultepec S.A. de C.V.
City
Morelia
ZIP/Postal Code
58260
Country
Mexico
Facility Name
SPZOZ Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa
City
Bialystok
ZIP/Postal Code
15-274
Country
Poland
Facility Name
Uniwersytecki Szpital Dziecięcy w Krakowie
City
Krakow
ZIP/Postal Code
30-663
Country
Poland
Facility Name
NZOZ TRI-medica
City
Lodz
ZIP/Postal Code
93-338
Country
Poland
Facility Name
Praktyka Lekarzy Rodzinnych R.Jadach, M.Domanski NZOZ
City
Wroclaw
ZIP/Postal Code
50-072
Country
Poland
Facility Name
LCS Clinical Research Unit
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2021
Country
South Africa
Facility Name
Soweto Clinical Trial Centre
City
Soweto
State/Province
Gauteng
ZIP/Postal Code
1818
Country
South Africa
Facility Name
Netcare St. Anne's Hospital
City
Pietermaritzburg
State/Province
KwaZulu-Natal
ZIP/Postal Code
3201
Country
South Africa
Facility Name
Groote Schuur Hospital E13 Renal Unit
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7925
Country
South Africa
Facility Name
Clinical Projects Research SA (PTY) LTD
City
Worcester
State/Province
Western Cape
ZIP/Postal Code
6850
Country
South Africa
Facility Name
CRISMO Bertha Gxowa Research Centre
City
Germiston
Country
South Africa
Facility Name
Cukurova University Medical Faculty
City
Adana
ZIP/Postal Code
01330
Country
Turkey
Facility Name
Gazi University Medical Faculty
City
Ankara
ZIP/Postal Code
06500
Country
Turkey
Facility Name
Istanbul University Istanbul Medical Faculty
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Facility Name
Dokuz Eylul University Medicine Faculty
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Facility Name
Erciyes University Medical Faculty
City
Kayseri
ZIP/Postal Code
38039
Country
Turkey
Facility Name
Celal Bayar University Medical Faculty
City
Manisa
ZIP/Postal Code
45040
Country
Turkey
Facility Name
CMI Chernivtsi City Children Clinical Hospital
City
Chernivtsi
Country
Ukraine
Facility Name
Regional Children CH Cardiology Department Kharkiv NMU
City
Kharkiv
Country
Ukraine
Facility Name
SI National Research Center of Radiation Medicine of NAMSU
City
Kyiv
Country
Ukraine
Facility Name
USPC of ES EO&T Transplantation of MHU
City
Kyiv
Country
Ukraine
Facility Name
HSEI of Ukraine UMSA
City
Poltava
Country
Ukraine
Facility Name
SSU Division MU Ch of pediatrics
City
Sumy
Country
Ukraine
Facility Name
Vynnitsa Regional Children CH pediatric department № 1 M.I. Pyrogov NMU
City
Vinnytsia
Country
Ukraine
Facility Name
CI Zaporizhzhia City Multibranch Children Hospital #5
City
Zaporizhzhia
Country
Ukraine
Facility Name
CI Zaporizhzhia Regional Clinical Children Hospital of ZRC
City
Zaporizhzhia
Country
Ukraine

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

We'll reach out to this number within 24 hrs